A Potential Treatment for HIV-Related Abdominal Obesity
In a placebo-controlled trial, daily tesamorelin injections reduced visceral adiposity and improved lipid profiles; however, the drug also led to a higher rate of treatment discontinuation because of adverse events than did placebo.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)